Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Clinical trial NCT04879043 · RECRUITING
Trial details
- NCT number
- NCT04879043
- Sponsor
- Heidelberg Pharma AG
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-07
- Primary completion
- 2028-03-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.